March 10, 2022 07:14 AM EST
Pharma
Cell/Gene Tx
Manufacturing

The of­fer does­n't stop at Covid. No­var­tis opens up man­u­fac­tur­ing ops to make Caris­ma’s CAR-M cell ther­a­py

Amber Tong

No­var­tis is dou­bling down on its con­tract man­u­fac­tur­ing busi­ness.

The phar­ma gi­ant lent a hand to Pfiz­er and BioN­Tech last year, de­ploy­ing fill-fin­ish sites …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times